在肝癌中,铁亡途径及其相关的分子无化修饰的研究进展
1The First Clinical Medical School, Guangdong Medical University, Zhanjiang, Guangdong, China.
Frontiers in oncology
|April 7, 2025
概括
细胞死亡过程 - - 铁亡 - - 通过诱导瘤细胞死亡,在肝癌治疗方面表现有前途. 乌比基因化调节了这一过程,为肝癌提供了新的治疗策略.
科学领域:
- 生物化学 生化学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 铁亡是一种编程细胞死亡的新型形式.
- 它的特点是铁的积累和反应性氧物种 (ROS) 的产生.
- 铁灭酶在癌症发育中起作用,并显示出在肝癌治疗中的潜力.
研究的目的:
- 为了审查ubiquitination在调节ferroptosis中的作用.
- 为了探索ubiquitination对ferroptosis路径中的分子的影响.
- 为新型肝癌治疗策略提供洞察力,以铁死为向.
主要方法:
- 关于铁和无处不在的现有研究的文献综述.
- 对分子机制的分析,将ubiquitination与ferroptosis联系起来.
- 检查使用ferroptosis治疗肝癌的研究.
主要成果:
- 蛋白质修饰的ubiquitination会影响蛋白质的稳定性和铁灭的进展.
- 特定的无处不在事件调节铁亡途径中的关键分子.
- 准无处不在提供了一个潜在的策略来诱导肝癌细胞中的铁亡.
结论:
- 乌比基化显著调节铁亡.
- 了解无处不在在铁亡中的作用为肝癌治疗提供了新的途径.
- 本综述强调了向肝癌中无化调节铁亡的治疗潜力.
更多相关视频
08:29SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
7.0K
10:26Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
5.5K
相关概念视频
Covalently Linked Protein Regulators
6.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
The Proteasome
781
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
781
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
